Randomized comparison of interferon α and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the …
R Hehlmann, U Berger, M Pfirrmann, A Hochhaus… - Leukemia, 2003 - nature.com
The optimum treatment conditions of interferon (IFN) α therapy in chronic myeloid leukemia
(CML) are still controversial. To evaluate the role of hydroxyurea (HU) for the outcome of IFN …
(CML) are still controversial. To evaluate the role of hydroxyurea (HU) for the outcome of IFN …
Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-α2b for chronic myeloid leukemia
Benelux CML Study Group - … Journal of the American Society of …, 1998 - ashpublications.org
Interferon-α (IFN-α) is considered the standard therapy for chronic myeloid leukemia (CML)
patients not suitable for allogeneic stem cell transplantation. From 1987 through 1992, 195 …
patients not suitable for allogeneic stem cell transplantation. From 1987 through 1992, 195 …
Interferon-alpha and hydroxyurea in early chronic myeloid leukemia: a comparative analysis of the Italian and German chronic myeloid leukemia trials with interferon …
J Hasford, M Baccarani, R Hehlmann, H Anseri, S Tura… - 1996 - ashpublications.org
In 1994, the Italian and the German Chronic myeloid leukemia (CML) trials comparing
interferon-alpha (IFN-alpha) with conventional chemotherapy were published. The survival …
interferon-alpha (IFN-alpha) with conventional chemotherapy were published. The survival …
Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous …
R Hehlmann, H Heimpel, DK Hossfeld… - Bone Marrow …, 1996 - europepmc.org
It is the long-term goal of the German CML Study Group and of the Süddeutsche
Hämoblastosegruppe (SHG) to improve survival of patients with chronic myelogenous …
Hämoblastosegruppe (SHG) to improve survival of patients with chronic myelogenous …
Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group [see comments]
R Hehlmann, H Heimpel, J Hasford, HJ Kolb, H Pralle… - 1994 - ashpublications.org
As curative bone marrow transplantation is available only to a minority of patients with
chronic myelogenous leukemia (CML), drug therapy remains of central interest. Several …
chronic myelogenous leukemia (CML), drug therapy remains of central interest. Several …
A prospective randomized study of alpha-2b interferon plus hydroxyurea or cytarabine for patients with early chronic phase chronic myelogenous leukemia: the …
FJ Giles, J Shan, S Chen, SH Advani… - Leukemia & …, 2000 - Taylor & Francis
A prospective randomized international study of 143 patients showed no apparent early
survival advantage conferred by combining cytarabine, rather than hydroxyurea, with INF as …
survival advantage conferred by combining cytarabine, rather than hydroxyurea, with INF as …
A randomized study comparing interferon (IFNα) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia …
T Kühr, S Burgstaller, U Apfelbeck, W Linkesch… - Leukemia Research, 2003 - Elsevier
This multicenter randomized phase III study was designed to compare the efficacy and
toxicity of IFNα-2c (3.5 MU/d) in combination with either araC (10mg/m2 d1-10) or …
toxicity of IFNα-2c (3.5 MU/d) in combination with either araC (10mg/m2 d1-10) or …
A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia
B Anger, F Porzsolt, R Leichtle, B Heinze, C Bartram… - Blut, 1989 - Springer
Nine previously untreated patients with Philadelphia chromosome-positive chronic
myelocytic leukemia (CML) were treated with recombinant interferon alpha 2a (rIFN-alpha …
myelocytic leukemia (CML) were treated with recombinant interferon alpha 2a (rIFN-alpha …
[HTML][HTML] Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia
F Guilhot, C Chastang, M Michallet… - … England Journal of …, 1997 - Mass Medical Soc
Background Treatment with interferon prolongs survival in chronic myelogenous leukemia.
We conducted a clinical trial to assess the efficacy of treatment with a combination of …
We conducted a clinical trial to assess the efficacy of treatment with a combination of …
Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials
Chronic Myeloid Leukemia Trialists' … - Journal of the …, 1997 - academic.oup.com
Background: Several randomized clinical trials in chronic myeloid leukemia (CML) have
reported better patient survival with interferon alfa (IFN α) than with standard …
reported better patient survival with interferon alfa (IFN α) than with standard …